{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T22:17:27Z","timestamp":1793139447675,"version":"4.5.0"},"reference-count":145,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Hemophagocytic lymphohistiocytosis (HLH) describes a severe, hyperinflammatory syndrome that can originate from diverse etiologies, often requiring critical care level management. Primary HLH, initially described in the 1940s, derives from genetic defects that result in uncontrolled immune activation. Although chemotherapy and immunosuppressive agents can temporarily quell inflammation, allogeneic hematopoietic cell transplantation (HCT) is the only curative option. In 2025, HCT is indicated for primary HLH and some etiologies of secondary HLH but remains challenging due to both disease and transplant-related inflammation. Additionally, new cellular therapy approaches to treat malignancy, such as chimeric antigen receptor T cells, can trigger a spectrum of hyperinflammatory complications. Herein, we review the pathophysiology, diagnosis, and evolving management approaches of primary and secondary HLH, ultimately informing our management of hyperinflammation in the setting of new cell therapies.<\/jats:p>","DOI":"10.3389\/fonc.2025.1631557","type":"journal-article","created":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T04:13:07Z","timestamp":1758255187000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Treating and triggering hyperinflammation: tackling hemophagocytic lymphohistiocytosis and HLH-like syndromes in the pediatric cell therapy and critical care setting"],"prefix":"10.3389","volume":"15","author":[{"given":"Holly","family":"Wobma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren A.","family":"Henderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine N.","family":"Duncan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan E.","family":"Prockop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrienne G.","family":"Randolph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara A.","family":"Degar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie E.","family":"Lehmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne H. C.","family":"Baumeister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00443367","article-title":"Familial hemophagocytic lymphohistiocytosis","volume":"140","author":"Janka","year":"1983","journal-title":"Eur J Pediatr"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/imr.13298","article-title":"Hemophagocytic lymphohistiocytosis: A disorder of T cell activation, immune regulation, and distinctive immunopathology","volume":"322","author":"Jordan","year":"2024","journal-title":"Immunol Rev"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/art.43052","article-title":"Macrophage activation syndrome","volume":"77","author":"Nigrovic","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14147","article-title":"Advances in the pathogenesis of primary and secondary haemophagocytic lymphohistiocytosis: differences and similarities","volume":"174","author":"Brisse","year":"2016","journal-title":"Br J Haematol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2023.07.008","article-title":"Frequency of HLA-DR(+)CD38(hi) T cells identifies and quantifies T-cell activation in hemophagocytic lymphohistiocytosis, hyperinflammation, and immune regulatory disorders","volume":"153","author":"Nguyen","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1172\/JCI165616","article-title":"Type I interferon signature and cycling lymphocytes in macrophage activation syndrome","volume":"133","author":"Huang","year":"2023","journal-title":"J Clin Invest"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009499","article-title":"T-cell activation profiles distinguish hemophagocytic lymphohistiocytosis and early sepsis","volume":"137","author":"Chaturvedi","year":"2021","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-10-3413","article-title":"An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder","volume":"104","author":"Jordan","year":"2004","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1136\/adc.27.136.519","article-title":"Familial haemophagocytic reticulosis","volume":"27","author":"Farquhar","year":"1952","journal-title":"Arch Dis Child"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-01-0172","article-title":"Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation","volume":"100","author":"Henter","year":"2002","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21039","article-title":"HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis","volume":"48","author":"Henter","year":"2007","journal-title":"Pediatr Blood Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024025077","article-title":"Diagnostic guidelines for familial hemophagocytic lymphohistiocytosis revisited","volume":"144","author":"Henter","year":"2024","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216030","article-title":"Adenosine deaminase 2 as a biomarker of macrophage activation syndrome in systemic juvenile idiopathic arthritis","volume":"79","author":"Lee","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/art.42636","article-title":"The 2022 EULAR\/ACR points to consider at the early stages of diagnosis and management of suspected haemophagocytic lymphohistiocytosis\/macrophage activation syndrome (HLH\/MAS)","volume":"75","author":"Shakoory","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1126\/science.286.5446.1957","article-title":"Perforin gene defects in familial hemophagocytic lymphohistiocytosis","volume":"286","author":"Stepp","year":"1999","journal-title":"Science"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001605","article-title":"Frequency and spectrum of disease-causing variants in 1892 patients with suspected genetic HLH disorders","volume":"4","author":"Gadoury-Levesque","year":"2020","journal-title":"Blood Adv"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000936","article-title":"Pediatric hemophagocytic lymphohistiocytosis","volume":"135","author":"Canna","year":"2020","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20190147","article-title":"A novel disorder involving dyshematopoiesis, inflammation, and HLH due to aberrant CDC42 function","volume":"216","author":"Lam","year":"2019","journal-title":"J Exp Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3089","article-title":"An activating NLRC4 inflammasome mutation causes autoinflammation with recurrent macrophage activation syndrome","volume":"46","author":"Canna","year":"2014","journal-title":"Nat Genet"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3893","article-title":"Inflammasomes: mechanism of action, role in disease, and therapeutics","volume":"21","author":"Guo","year":"2015","journal-title":"Nat Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/nature05257","article-title":"XIAP deficiency in humans causes an X-linked lymphoproliferative syndrome","volume":"444","author":"Rigaud","year":"2006","journal-title":"Nature"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19800515)45:10<2516::AID-CNCR2820451008>3.0.CO;2-V","article-title":"Successful treatment of lymphohistiocytic reticulosis with phagocytosis with epipodophyllotoxin VP 16-213","volume":"45","author":"Ambruso","year":"1980","journal-title":"Cancer"},{"key":"B23","doi-asserted-by":"publisher","first-page":"84","DOI":"10.4049\/jimmunol.1302282","article-title":"Etoposide selectively ablates activated T cells to control the immunoregulatory disorder hemophagocytic lymphohistiocytosis","volume":"192","author":"Johnson","year":"2014","journal-title":"J Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11940-017-0439-4","article-title":"How to treat involvement of the central nervous system in hemophagocytic lymphohistiocytosis","volume":"19","author":"Horne","year":"2017","journal-title":"Curr Treat Options Neurol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-06-356261","article-title":"Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol","volume":"118","author":"Trottestam","year":"2011","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2018.05.031","article-title":"Recommendations for the use of etoposide-based therapy and bone marrow transplantation for the treatment of HLH: consensus statements by the HLH steering committee of the histiocyte society","volume":"6","author":"Ehl","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-03-278127","article-title":"How I treat hemophagocytic lymphohistiocytosis","volume":"118","author":"Jordan","year":"2011","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911326","article-title":"Emapalumab in children with primary hemophagocytic lymphohistiocytosis","volume":"382","author":"Locatelli","year":"2020","journal-title":"N Engl J Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014860","article-title":"A study of ruxolitinib response-based stratified treatment for pediatric hemophagocytic lymphohistiocytosis","volume":"139","author":"Zhang","year":"2022","journal-title":"Blood"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024025977","article-title":"Emapalumab therapy for hemophagocytic lymphohistiocytosis before reduced-intensity transplantation improves chimerism","volume":"144","author":"Verkamp","year":"2024","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-12-684498","article-title":"The minimum required level of donor chimerism in hereditary hemophagocytic lymphohistiocytosis","volume":"127","author":"Hartz","year":"2016","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1016\/j.jaci.2021.07.031","article-title":"Comparison of hematopoietic cell transplant conditioning regimens for hemophagocytic lymphohistiocytosis disorders","volume":"149","author":"Marsh","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-020-00814-6","article-title":"Neuroinflammatory disease as an isolated manifestation of hemophagocytic lymphohistiocytosis","volume":"40","author":"Blincoe","year":"2020","journal-title":"J Clin Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000560","article-title":"Pediatric CNS-isolated hemophagocytic lymphohistiocytosis","volume":"6","author":"Benson","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018027417","article-title":"Central nervous system-restricted familial hemophagocytic lymphohistiocytosis responds to hematopoietic cell transplantation","volume":"3","author":"Li","year":"2019","journal-title":"Blood Adv"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1080\/25785826.2021.1912893","article-title":"Macrophage activation syndrome in systemic juvenile idiopathic arthritis","volume":"44","author":"Shimizu","year":"2021","journal-title":"Immunol Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20050473","article-title":"Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade","volume":"201","author":"Pascual","year":"2005","journal-title":"J Exp Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-014-3059-2","article-title":"Serum IL-18 as a potential specific marker for differentiating systemic juvenile idiopathic arthritis from incomplete Kawasaki disease","volume":"35","author":"Takahara","year":"2015","journal-title":"Rheumatol Int"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu524","article-title":"Cytokines in systemic juvenile idiopathic arthritis and haemophagocytic lymphohistiocytosis: tipping the balance between interleukin-18 and interferon-gamma","volume":"54","author":"Put","year":"2015","journal-title":"Rheumatol (Oxford)"},{"key":"B40","article-title":"International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001","volume":"31","author":"Petty","year":"2004","journal-title":"J Rheumatol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1002\/art.38615.","article-title":"Review: is there a window of opportunity for treatment of systemic juvenile idiopathic arthritis","volume":"66","author":"Nigrovic","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1002\/art.39332","article-title":"2016 Classification criteria for macrophage activation syndrome complicating systemic\u00a0juvenile idiopathic arthritis: A european league against rheumatism\/American college\u00a0of rheumatology\/Paediatric rheumatology international trials organisation collaborative initiative","volume":"68","author":"Ravelli","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2015.06.005","article-title":"Interleukin-18 for predicting the development of macrophage activation syndrome in systemic juvenile idiopathic arthritis","volume":"160","author":"Shimizu","year":"2015","journal-title":"Clin Immunol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"6915","DOI":"10.1038\/s41467-022-34480-6","article-title":"mTORC1 links pathology in experimental models of Still\u2019s disease and macrophage activation syndrome","volume":"13","author":"Huang","year":"2022","journal-title":"Nat Commun"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1101\/2024.03.13.24304215","article-title":"Enrichment of rare variants of hemophagocytic lymphohistiocytosis genes in systemic juvenile idiopathic arthritis","volume":"76","author":"Correia Marques","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24853","article-title":"2021 American college of rheumatology guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for oligoarthritis, temporomandibular joint arthritis, and systemic juvenile idiopathic arthritis","volume":"74","author":"Onel","year":"2022","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.134254","article-title":"A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)","volume":"70","author":"Quartier","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1205099","article-title":"Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis","volume":"367","author":"Ruperto","year":"2012","journal-title":"N Engl J Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112802","article-title":"Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis","volume":"367","author":"De Benedetti","year":"2012","journal-title":"N Engl J Med"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1002\/art.42037","article-title":"2021 American college of rheumatology guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for oligoarthritis, temporomandibular joint arthritis, and systemic juvenile idiopathic arthritis","volume":"74","author":"Onel","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac440","article-title":"JAK inhibitors in difficult-to-treat adult-onset Still\u2019s disease and systemic-onset juvenile idiopathic arthritis","volume":"62","author":"Gillard","year":"2023","journal-title":"Rheumatol (Oxford)"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19803","article-title":"Ruxolitinib-based regimen in children with autoimmune disease or autoinflammatory disease-related haemophagocytic lymphohistiocytosis","volume":"206","author":"Fang","year":"2025","journal-title":"Br J Haematol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2013.00180","article-title":"Decoys and regulatory \u201cReceptors\u201d of the IL-1\/toll-like receptor superfamily","volume":"4","author":"Garlanda","year":"2013","journal-title":"Front Immunol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.211219","article-title":"An evidence-based guideline improves outcomes for patients with hemophagocytic lymphohistiocytosis and macrophage activation syndrome","volume":"49","author":"Taylor","year":"2022","journal-title":"J Rheumatol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12969-019-0309-6","article-title":"Calm in the midst of cytokine storm: a collaborative approach to the diagnosis and\u00a0treatment of hemophagocytic lymphohistiocytosis and macrophage activation\u00a0syndrome","volume":"17","author":"Halyabar","year":"2019","journal-title":"Pediatr Rheumatol Online J"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223739","article-title":"Efficacy and safety of emapalumab in macrophage activation syndrome","volume":"82","author":"De Benedetti","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"B57","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1093\/rheumatology\/keae391","article-title":"Current treatment in macrophage activation syndrome worldwide: a systematic literature review to inform the METAPHOR project","volume":"64","author":"Baldo","year":"2025","journal-title":"Rheumatol (Oxford)"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.200941","article-title":"Efficacy of moderately dosed etoposide in macrophage activation syndrome-hemophagocytic lymphohistiocytosis","volume":"48","author":"Horne","year":"2021","journal-title":"J Rheumatol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1002\/art.22656","article-title":"Autologous stem cell transplantation in children with severe progressive systemic or polyarticular juvenile idiopathic arthritis: long-term follow-up of a prospective clinical trial","volume":"56","author":"Brinkman","year":"2007","journal-title":"Arthritis Rheumatol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.017798","article-title":"Autologous stem cell transplantation for refractory juvenile idiopathic arthritis: analysis of clinical effects, mortality, and transplant related morbidity","volume":"63","author":"De Kleer","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216040","article-title":"Emergent high fatality lung disease in systemic juvenile arthritis","volume":"78","author":"Saper","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1002\/acr.25234","article-title":"Disease course, treatments, and outcomes of children with systemic juvenile idiopathic arthritis-associated lung disease","volume":"76","author":"Huang","year":"2024","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1002\/art.41073","article-title":"Systemic juvenile idiopathic arthritis-associated lung disease: characterization and risk factors","volume":"71","author":"Schulert","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.11600","article-title":"Development of a screening algorithm for lung disease in systemic juvenile idiopathic arthritis","volume":"5","author":"Wobma","year":"2023","journal-title":"ACR Open Rheumatol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1002\/acr.25129","article-title":"Incidence and risk factors for eosinophilia and lung disease in biologic-exposed children with systemic juvenile idiopathic arthritis","volume":"75","author":"Wobma","year":"2023","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.2024-0180","article-title":"Severe features of systemic juvenile idiopathic arthritis in patients with congenital heart disease","volume":"51","author":"Aires","year":"2024","journal-title":"J Rheumatol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.147593","article-title":"IFN-gamma is essential for alveolar macrophage-driven pulmonary inflammation in macrophage activation syndrome","volume":"6","author":"Gao","year":"2021","journal-title":"JCI Insight"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1908129116","article-title":"Trisomy 21 dysregulates T cell lineages toward an autoimmunity-prone state associated with interferon hyperactivity","volume":"116","author":"Araya","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017014449","article-title":"Allogeneic hematopoietic stem cell transplantation for severe, refractory juvenile idiopathic arthritis","volume":"2","author":"MFS","year":"2018","journal-title":"Blood Adv"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(24)00275-3","article-title":"Allogeneic haematopoietic stem-cell transplantation for children with refractory systemic juvenile idiopathic arthritis and associated lung disease: outcomes from an international, retrospective cohort study","volume":"7","author":"Matt","year":"2024","journal-title":"Lancet Rheumatol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jcv.2018.03.001","article-title":"Primary Epstein-Barr virus infection","volume":"102","author":"Dunmire","year":"2018","journal-title":"J Clin Virol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2024.11.029","article-title":"Features of hyperinflammation link the biology of Epstein-Barr virus infection and cytokine storm syndromes","volume":"155","author":"Liu","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12386","article-title":"Treatment of Epstein Barr virus-induced haemophagocytic lymphohistiocytosis with rituximab-containing chemo-immunotherapeutic regimens","volume":"162","author":"Chellapandian","year":"2013","journal-title":"Br J Haematol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1097\/00003246-199401000-00008","article-title":"Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial","volume":"22","author":"Fisher","year":"1994","journal-title":"Crit Care Med"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1994.03510470040032","article-title":"Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group","volume":"271","author":"Fisher","year":"1994","journal-title":"JAMA"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1002\/art.41103","article-title":"Benefit of anakinra in treating pediatric secondary hemophagocytic lymphohistiocytosis","volume":"72","author":"Eloseily","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.trim.2024.102162","article-title":"Low-dose emapalumab combined with chemotherapy for adult patients with Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis","volume":"88","author":"Zhu","year":"2024","journal-title":"Transpl Immunol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000039880","article-title":"Emapalumab as a therapeutic intervention for Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis: A case series","volume":"103","author":"Wang","year":"2024","journal-title":"Med (Baltimore)"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01902","article-title":"Epstein-barr virus and hemophagocytic lymphohistiocytosis","volume":"8","author":"Marsh","year":"2017","journal-title":"Front Immunol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1182\/blood.2023021074","article-title":"Chronic active Epstein-Barr virus disease originates from infected hematopoietic stem cells","volume":"143","author":"Wang","year":"2024","journal-title":"Blood"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-023-03660-5","article-title":"Updated guidelines for chronic active Epstein-Barr virus disease","volume":"118","author":"Kawada","year":"2023","journal-title":"Int J Hematol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1186\/s13023-023-02861-9","article-title":"Sintilimab treatment for chronic active Epstein-Barr virus infection and Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in children","volume":"18","author":"Chen","year":"2023","journal-title":"Orphanet J Rare Dis"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26544","article-title":"Registry data analysis of hematopoietic stem cell transplantation on systemic chronic active Epstein-Barr virus infection patients in Japan","volume":"97","author":"Yamamoto","year":"2022","journal-title":"Am J Hematol"},{"key":"B84","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/bmt.2010.122","article-title":"Excellent outcome of allogeneic hematopoietic SCT with reduced-intensity conditioning for the treatment of chronic active EBV infection","volume":"46","author":"Kawa","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023020715","article-title":"Malignancy-associated hemophagocytic lymphohistiocytosis in Sweden: incidence, clinical characteristics, and survival","volume":"143","author":"Lofstedt","year":"2024","journal-title":"Blood"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13462","article-title":"Malignancy-associated haemophagocytic lymphohistiocytosis in children and adolescents","volume":"170","author":"Lehmberg","year":"2015","journal-title":"Br J Haematol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30084","article-title":"Malignancy-associated hemophagocytic lymphohistiocytosis in adults: Relation to hemophagocytosis, characteristics, and outcomes","volume":"122","author":"Tamamyan","year":"2016","journal-title":"Cancer"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021012764","article-title":"An improved index for diagnosis and mortality prediction in Malignancy-associated hemophagocytic lymphohistiocytosis","volume":"139","author":"Zoref-Lorenz","year":"2022","journal-title":"Blood"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2018894618","article-title":"Recommendations for the management of hemophagocytic lymphohistiocytosis in adults","volume":"133","author":"La Rosee","year":"2019","journal-title":"Blood"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.220301","article-title":"Dose-adjusted EPOCH regimen as first-line treatment for non-Hodgkin lymphoma-associated hemophagocytic lymphohistiocytosis: a single-arm, open-label, phase II trial","volume":"105","author":"Liang","year":"2020","journal-title":"Haematologica"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2107725","article-title":"CD19-targeted CAR T cells in refractory systemic lupus erythematosus","volume":"385","author":"Mougiakakos","year":"2021","journal-title":"N Engl J Med"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000001062","article-title":"Releasing our model T - chimeric antigen receptor (CAR) T-cells for autoimmune indications","volume":"37","author":"Wobma","year":"2024","journal-title":"Curr Opin Rheumatol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-16-0040","article-title":"Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"6","author":"Teachey","year":"2016","journal-title":"Cancer Discov"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002394","article-title":"Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Locke","year":"2020","journal-title":"Blood Adv"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-024-00903-0","article-title":"Current understanding and management of CAR T cell-associated toxicities","volume":"21","author":"Brudno","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0737-3","article-title":"Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma","volume":"26","author":"Brudno","year":"2020","journal-title":"Nat Med"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0549-5","article-title":"Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR","volume":"25","author":"Ghorashian","year":"2019","journal-title":"Nat Med"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(24)00402-8","article-title":"Safety of CAR T-cell therapy for cancer in pre-existing autoimmune or inflammatory disease: a retrospective comparative cohort study","volume":"7","author":"Vanni","year":"2025","journal-title":"Lancet Rheumatol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(25)00091-8","article-title":"Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with autoimmune disease: an observational study","volume":"7","author":"Hagen","year":"2025","journal-title":"Lancet Rheumatol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001463","article-title":"Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy","volume":"134","author":"Gardner","year":"2019","journal-title":"Blood"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat Med"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat Med"},{"key":"B108","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01992","article-title":"Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline","volume":"39","author":"Santomasso","year":"2021","journal-title":"J Clin Oncol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00474-4","article-title":"Diagnosis, grading and management of toxicities from immunotherapies in\u00a0children, adolescents and young adults with cancer","volume":"18","author":"Ragoonanan","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022006983","article-title":"Anakinra utilization in refractory pediatric CAR T-cell associated toxicities","volume":"6","author":"Diorio","year":"2022","journal-title":"Blood Adv"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021011898","article-title":"Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells","volume":"138","author":"Lichtenstein","year":"2021","journal-title":"Blood"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02220-y","article-title":"CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: Phase 1b results","volume":"38","author":"Schultz","year":"2024","journal-title":"Leukemia"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.03.006","article-title":"Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome","volume":"29","author":"Hines","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008893","article-title":"HLH-like toxicities predict poor survival after the use of tisagenlecleucel in children and young adults with B-ALL","volume":"7","author":"McNerney","year":"2023","journal-title":"Blood Adv"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1543622","article-title":"Emapalumab for severe cytokine release syndrome in solid tumor CAR-T: a case report","volume":"15","author":"Ruemmele","year":"2025","journal-title":"Front Oncol"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010708","article-title":"Free interleukin-18 is elevated in CD22 CAR T-cell-associated hemophagocytic lymphohistiocytosis-like toxicities","volume":"7","author":"Rocco","year":"2023","journal-title":"Blood Adv"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019001272","article-title":"Identification of germline variants in adults with hemophagocytic lymphohistiocytosis","volume":"4","author":"Miller","year":"2020","journal-title":"Blood Adv"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008206","article-title":"Contribution of clonal hematopoiesis to adult-onset hemophagocytic lymphohistiocytosis","volume":"136","author":"Miller","year":"2020","journal-title":"Blood"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1172\/JCI130059","article-title":"Perforin-deficient CAR T cells recapitulate late-onset inflammatory toxicities observed in patients","volume":"130","author":"Ishii","year":"2020","journal-title":"J Clin Invest"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010712","article-title":"Emapalumab for the treatment of refractory cytokine release syndrome in pediatric patients","volume":"7","author":"Schuelke","year":"2023","journal-title":"Blood Adv"},{"key":"B122","doi-asserted-by":"publisher","first-page":"3423","DOI":"10.1038\/s41467-023-38723-y","article-title":"Neutralizing IFNgamma improves safety without compromising efficacy of CAR-T cell therapy in B-cell Malignancies","volume":"14","author":"Manni","year":"2023","journal-title":"Nat Commun"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-21-0181","article-title":"Blockade or deletion of IFNgamma reduces macrophage activation without compromising CAR T-cell function in hematologic Malignancies","volume":"3","author":"Bailey","year":"2022","journal-title":"Blood Cancer Discov"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04585-5","article-title":"CAR T cell killing requires the IFNgammaR pathway in solid but not liquid tumours","volume":"604","author":"Larson","year":"2022","journal-title":"Nature"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2314005","article-title":"Hemophagocytic lymphohistiocytosis","volume":"392","author":"Henter","year":"2025","journal-title":"N Engl J Med"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1282804","article-title":"HLH as an additional warning sign of inborn errors of immunity beyond familial-HLH in children: a systematic review","volume":"15","author":"Ricci","year":"2024","journal-title":"Front Immunol"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000005361","article-title":"Consensus-based guidelines for the recognition, diagnosis, and management of hemophagocytic lymphohistiocytosis in critically ill children and adults","volume":"50","author":"Hines","year":"2022","journal-title":"Crit Care Med"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.RA119.008903","article-title":"Magnesium transporter 1 (MAGT1) deficiency causes selective defects in N-linked glycosylation and expression of immune-response genes","volume":"294","author":"Matsuda-Lennikov","year":"2019","journal-title":"J Biol Chem"},{"key":"B129","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1084\/jem.20160784","article-title":"Inherited CD70 deficiency in humans reveals a critical role for the CD70-CD27 pathway in immunity to Epstein-Barr virus infection","volume":"214","author":"Izawa","year":"2017","journal-title":"J Exp Med"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1038\/nature13386","article-title":"CTP synthase 1 deficiency in humans reveals its central role in lymphocyte proliferation","volume":"510","author":"Martin","year":"2014","journal-title":"Nature"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3575","article-title":"RASGRP1 deficiency causes immunodeficiency with impaired cytoskeletal dynamics","volume":"17","author":"Salzer","year":"2016","journal-title":"Nat Immunol"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.70962\/jhi.20250002","article-title":"The 2024 update of IUIS phenotypic classification of human inborn errors of immunity","volume":"1","author":"Aziz Bousfiha","year":"2025","journal-title":"J Hum Immunity"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-018-0046-y","article-title":"Biology and regulation of IL-2: from molecular mechanisms to human therapy","volume":"18","author":"Spolski","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.141.3.849","article-title":"Simultaneous production of IL-2, IL-4, and IFN-gamma by activated human CD4+ and CD8+ T cell clones","volume":"141","author":"Paliard","year":"1988","journal-title":"J Immunol"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a028480","article-title":"Interferon gamma and its important roles in promoting and inhibiting spontaneous and therapeutic cancer immunity","volume":"11","author":"Alspach","year":"2019","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"B136","doi-asserted-by":"publisher","first-page":"a016295","DOI":"10.1101\/cshperspect.a016295","article-title":"IL-6 in inflammation, immunity, and disease","volume":"6","author":"Tanaka","year":"2014","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-07-273417","article-title":"Interleukin-1 in the pathogenesis and treatment of inflammatory diseases","volume":"117","author":"Dinarello","year":"2011","journal-title":"Blood"},{"key":"B138","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1161\/ATVBAHA.110.207449","article-title":"Prostaglandins and inflammation","volume":"31","author":"Ricciotti","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B139","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41584-023-01053-w","article-title":"Biological and clinical roles of IL-18 in inflammatory diseases","volume":"20","author":"Landy","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2025.03.002","article-title":"Role of hematopoietic cell transplantation in pediatric and adult hemophagocytic lymphohistiocytosis-remaining unknowns and challenges","volume":"39","author":"Nikiforow","year":"2025","journal-title":"Hematol Oncol Clin North Am"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005956","article-title":"Dasatinib for treatment of CAR T-cell therapy-related complications","volume":"10","author":"Baur","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024013688","article-title":"Siltuximab for chimeric antigen receptor T-cell therapy-related CRS and ICANS: a multicenter retrospective analysis","volume":"9","author":"Bajwa","year":"2025","journal-title":"Blood Adv"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.30741","article-title":"Intrathecal hydrocortisone for treatment of children and young adults with CAR T-cell immune-effector cell-associated neurotoxicity syndrome","volume":"71","author":"Shalabi","year":"2024","journal-title":"Pediatr Blood Cancer"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001626","article-title":"Intrathecal chemotherapy for management of steroid-refractory CAR T-cell-associated neurotoxicity syndrome","volume":"4","author":"Shah","year":"2020","journal-title":"Blood Adv"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2025.02.005","article-title":"Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS)","volume":"39","author":"Lee","year":"2025","journal-title":"Hematol Oncol Clin North Am"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1631557\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T04:13:12Z","timestamp":1758255192000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1631557\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,19]]},"references-count":145,"alternative-id":["10.3389\/fonc.2025.1631557"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1631557","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,19]]},"article-number":"1631557"}}